Fusion Antibodies Announces Director Dealings
Why we think this is neutral
This RNS announcement is related to director dealings, which does not fall under the mandatory news types that require detailed analysis. As a result, the sentiment score is set to neutral.
Key Points
- Canaccord Genuity Group Inc. and its subsidiaries have acquired a 7.1182% stake in Fusion Antibodies plc
Summary
The healthcare company has announced changes to its major shareholders.
Fusion Antibodies plc, a contract research organization in the healthcare sector, has announced changes to its major shareholders. The announcement details the acquisition of a 7.1182% stake in the company by Canaccord Genuity Group Inc. and its subsidiaries.
DIRECTOR DEALINGS